|
Getting your Trinity Audio player ready...
|
Evofem Biosciences Inc (OTCMKTS:EVFM) is an innovative biotech company that is squarely focused on a niche market, unmet needs in the women’s reproductive and sexual health market. It develops and commercializes products in that niche.
As it happens, Evofem Biosciences has already managed to get one of its products, Phexxi, to get approval from the United States Food and Drug Administration. The product in question is an on-demand prescription contraceptive vaginal gel that is free of hormones. The product has been made available by the company in the form of 12 pre-filled applicators and the customer needs to apply it 0-60 minutes prior to the sexual act.
The company had been in focus last week on April 14 when it announced that it had appointed a new Chief Financial Officer and Secretary in the form of Ivy Zhang. The appointment had gone into effect on April 13. In this role, Zhang would report directly to the Chief Executive Officer of Evofem Biosciences Saundra Pelletier. It should be noted in this regard that Zhang will be the one to head the company’s financial activities and finance organization.
That would include accounting, financial planning, analysis, treasury functions, external audit, and controllership. Pelletier spoke about the new appointment as well. She noted that everyone at the company was delighted at the possibility of welcoming Zhang to her new role. Pelletier went on to add that Zhang not only had the entrepreneurial pedigree and growth focussed mindset but also had a deep knowledge of the Evofem culture.